RxDoctor Payments Data

Sabrina Mentock, MD

Family Medicine · Durham, NCNPI 1841346947

Payments from drug & device makers

$6,221in general payments, 2019–2025

Across 342 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$997
  • Amgen$710
  • Pfizer$501
  • Bausch Health US, LLC$468
  • Novo Nordisk$415
  • Lilly USA, LLC$397
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,191100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,221 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,109
Medicare patients
69
Services billed
316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$28,475
FarxigaDapagliflozin Propanediol34$25,127
OzempicSemaglutide21$23,733
Tresiba Flextouch U-200Insulin Degludec20$19,485
JardianceEmpagliflozin15$17,038
Repatha SureclickEvolocumab22$15,566
TrintellixVortioxetine Hydrobromide11$9,006
VascepaIcosapent Ethyl16$8,446
XareltoRivaroxaban11$6,135
SynthroidLevothyroxine Sodium16$2,182
Lubiprostone17$1,525
Nebivolol Hcl19$1,404
Rosuvastatin Calcium131$1,075
Ezetimibe43$1,012
Bupropion XlBupropion Hcl22$800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$397$28,47527 claims
AstraZenecaFarxiga$141$25,12734 claims
Novo NordiskOzempic$415$23,73321 claims
Boehringer IngelheimJardiance$51$17,03815 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$376$9,00611 claims
Johnson & JohnsonXarelto$81$6,13511 claims
AbbVieSynthroid$997$2,18216 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$164$29339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →